Research shows that after 60 months of treatment, 38% of patients achieved complete remission.
More than one-third of patients with severe atopic dermatitis (AD), a chronic disease characterized by inflammation of the skin and skin barrier defects, were in complete remission after taking Dupixent (dupilumab) for five years, according to a new study.
The research, published in the Journal of Dermatological Treatment, analyzed data from more than 700 patients receiving Dupixent. Led by Francesca Barei, M.D., of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, is only the second to look at real world results for patients on the therapy for five years or longer. The study found that 60 months of treatment, 38% of patients achieved complete remission, while 91% experienced at least a 90% improvement in their eczema scores. Additionally, 83% of patients reported either no itch or only mild itching.
“This investigation establishes dupilumab’s enduring efficacy and safety in severe AD, emphasizing its potential as a sustained therapeutic option over 5+ years,” the study authors wrote.
The researchers also looked at factors that might predict why some patients stop treatment, finding people with a specific type of the condition, called nummular eczema, characterized by round, coin-shaped patches of inflamed skin had a higher risk of developing psoriasis while on Dupixent, leading them to discontinue taking the medicine. The study authors wrote this was the first research paper to report the correlation.
While the occurrence of Dupixent-associated psoriasis is a known adverse event, this finding suggests that patients with certain atopic dermatitis phenotypes may require closer monitoring during treatment.
Dupixent is a monoclonal antibody that blocks interleukin-4 (IL-4), which has a cascading effect on the production of proinflammatory cytokines and chemokines. Other systematic therapies for AD include Ebglyss (lebrikizumab), Cibinqo (abrocitinib) and Rinvoq (upadacitinib).
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
July 8th 2025AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.
Read More
Higher Air Pollution and Extreme Weather Linked to Adult Atopic Dermatitis
July 1st 2025Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic dermatitis (AD), the most common chronic inflammatory skin condition, affecting up to 15% of people worldwide.
Read More
Teens With Hidradenitis Suppurativa Face Higher Risk of Chronic Health and Mental Health Conditions
June 16th 2025In a national study of 55 million children and teens across the U.S., there were 1,240 confirmed cases of hidradenitis suppurativa (HS). Nearly all were aged 10 or older.
Read More